LifeMD Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
-9.6%projected annual EPS growth
Analyst Coverage
8analysts covering
FY Revenue (est.)
$222Mnext fiscal year
FY EPS (est.)
$0.14next fiscal year
Reporting Calendar
| Event | Expected Date |
|---|---|
| Q3 2026 Earnings Release | 20 Nov 2026 |
Monitoring Framework
Key Performance Indicators
Active Telehealth Subscribers Quarterly365K
Gross Margin Quarterly88.0%
Insurance Covered Lives Quarterly112M
Weight Management Program Subscribers Quarterly100K
Watch Items
- Revenue Cycle Management (RCM) Billing DelaysTrigger: Delayed cash flows or increased write-offs during transition to commercial insurance and Medicare AdvantageAction: Optimize internal billing workflows and enhance claims collection systems under the direction of the new CFO and CTO
- Customer Acquisition Cost (CAC) InflationTrigger: Ad rate increases by competitors (e.g., Hims & Hers, Ro) compressing marketing efficiencyAction: Monitor marketing spend efficiency and adjust front-loaded patient acquisition investments
- Regulatory Crackdowns on 503A CompoundingTrigger: FDA or FTC warnings/restrictions on compounded semaglutide or hormone therapiesAction: Accelerate transition to branded pharmaceutical partnerships (e.g., Novo Nordisk, Eli Lilly) and ensure strict compliance
Research as of 20 Jun 2026